Skip to main content
SpringerLink
Log in

Factors affecting survival time after recurrence of non-small-cell lung cancer treated with concurrent chemoradiotherapy

  • Original article
  • Published:
Japanese Journal of Radiology Aims and scope Submit manuscript

Abstract

Purpose

Dose-fractionation schedules of palliative or salvage radiotherapy (RT) for recurrence of non-small-cell lung cancer (NSCLC) are various because they highly depend on patient prognosis. For optimal selection of dose-fractionation schedules, factors affecting survival time after recurrence were examined.

Materials and methods

From 1992 to 2005, 115 patients with stage III NSCLC received curative-intent concurrent chemoradiotherapy (CCRT). Among these patients, 74 underwent recurrence and were reviewed. Evaluated factors were age at recurrence, gender, initial stage, histological subtype, initial radiation-field size, recurrent patterns (locoregional alone vs. distant ± locoregional), time to recurrence (≤6 vs. >6 months), and treatment for recurrence (chemotherapy, RT).

Results

Median follow-up time after recurrence was 7 (range 0–59) months. One- and 2-year overall survival rates after recurrence were 28 and 11%, respectively. Based on multivariate analysis, time to recurrence (p = 0.0001) and administration of chemotherapy for recurrence (p = 0.0190) were the independently significant factors.

Conclusions

Early recurrence was the most significant factor for survival after post-CCRT recurrence of NSCLC. Administration of chemotherapy for recurrence was also a significant factor, whereas RT for recurrence was not significant. When RT was given to patients with post-CCRT recurrence of NSCLC, dose-fractionated schedules should be determined considering these factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALCB) 8433 trial. J Natl Cancer Inst. 1996;88:1210–5.

    Article  PubMed  CAS  Google Scholar 

  2. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692–9.

    PubMed  CAS  Google Scholar 

  3. Beck-Bornholdt HP, Dubben HH. Potential pitfalls in the use of p-values and in interpretation of significance levels. Radiother Oncol. 1994;33:171–6.

    Article  PubMed  CAS  Google Scholar 

  4. Macbeth FR, Bolger JJ, Hopwood P, Bleehen NM, Cartmell J, Girling DJ, Machin D, Stephens RJ, Bailey AJ. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol). 1996;8:167–75.

    Article  CAS  Google Scholar 

  5. Bezjak A, Dixon P, Brundage M, Tu D, Palmer MJ, Blood P, Grafton C, Lochrin C, Leong C, Mulroy L, Smith C, Wright J, Pater JL, Clinical Trials Group of the National Cancer Institute of Canada. Randomized phase III trial of single versus fractionated thoracic radiation in palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys. 2002;54:719–28.

    Article  PubMed  Google Scholar 

  6. Lu JJ, Allison RR. Non-small cell lung cancer. In: Lu JJ, Brady LW, editors. Radiation oncology. An evidenced-based approach. Berlin: Springer; 2008. p. 131–146.

  7. Okamoto Y, Murakami M, Yoden E, Sasaki R, Okuno Y, Nakajima T, Kuroda Y. Reirradiation for locally recurrent lung cancer previously treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2002;52:390–6.

    Article  PubMed  Google Scholar 

  8. Tada T, Fukuda H, Matsui K, Hirashima T, Hosono M, Takada Y, Inoue Y. Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapy. Int J Clin Oncol. 2005;10:247–50.

    Article  PubMed  Google Scholar 

  9. Cetingoz R, Arican-Alicikus Z, Nur-Demiral A, Durmak-Isman B, Bakis-Altas B, Kinay M. Is re-irradiation effective in symptomatic local recurrence of non small cell lung cancer patients? A single institution experience and review of the literature. J BUON. 2009;14:33–40.

    PubMed  CAS  Google Scholar 

  10. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P, International Staging Committee and Participating Institutions. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition. J Thorac Oncol. 2008;3:457–66.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, National Hospital Organization Shikoku Cancer Center, Kou-160, Minamiumemoto-Machi, Matsuyama, Ehime, 791-0280, Japan

    Yasushi Hamamoto, Masaaki Kataoka & Shuichi Shinohara

  2. Department of Thoracic Oncology, Shikoku Cancer Center, Kou-160, Minamiumemoto-Machi, Matsuyama, Ehime, 791-0280, Japan

    Naoyuki Nogami, Toshiyuki Kozuki, Yuka Kato & Tetsu Shinkai

Authors
  1. Yasushi Hamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masaaki Kataoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naoyuki Nogami
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshiyuki Kozuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuka Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shuichi Shinohara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tetsu Shinkai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yasushi Hamamoto.

About this article

Cite this article

Hamamoto, Y., Kataoka, M., Nogami, N. et al. Factors affecting survival time after recurrence of non-small-cell lung cancer treated with concurrent chemoradiotherapy. Jpn J Radiol 30, 249–254 (2012). https://doi.org/10.1007/s11604-011-0040-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11604-011-0040-9

Keywords

Search

Navigation